Cigna Investments’s Meridian Bioscience Inc VIVO Stock Holding History

Cigna Investments’s Portfolio VIVO Stock Details VIVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-14,611	Closed	-$208K	–	828
2018 Q1	$208K	Hold	14,611	–	–	0.01%	773
2017 Q4	$205K	Sell	14,611 -700	-5%	-$10.2K	0.01%	843
2017 Q3	$220K	Hold	15,311	–	–	0.01%	795
2017 Q2	$241K	Buy	+15,311	New	+$221K	0.02%	706

Other funds holding VIVO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cigna Investments's VIVO Position: Q2 2018 in Review

Cigna Investments sold out of Meridian Bioscience Inc (VIVO) in Q2 2018, closing a stake of 14,611 shares — an estimated $208K sold.

Cigna Investments first reported a position in VIVO in Q2 2017 and held it in 4 quarters. The position peaked at $241K in Q2 2017. 177 funds tracked by Wall St. Rank hold VIVO as of Q2 2018.

Cigna Investments reported no remaining Meridian Bioscience Inc position as of Q2 2018 after selling out during the quarter.
Cigna Investments sold 14,611 Meridian Bioscience Inc shares in Q2 2018, an estimated $208K.
Cigna Investments first reported a position in Meridian Bioscience Inc in Q2 2017 and held it in 4 quarters.
Cigna Investments's Meridian Bioscience Inc position peaked at $241K in Q2 2017.
177 funds tracked by Wall St. Rank held Meridian Bioscience Inc as of Q2 2018.

Based on Cigna Investments's 13F filing for Q2 2018, filed 14 Aug 2018.